• 1
    Andersson K-E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993;45:253.
  • 2
    Anderson K-E, Yoshida M. Antimuscarinics and the overactive bladder — which is the main mechanism of action? Eurpoean Urol 2003;1:15.DOI: 10.1016/S0302-2838(02)00540-7
  • 3
    Cardozo LD, Cooper D, Versi E. Oxybutynin chloride in the management of idiopathic detrusor instability. BMJ 1987;280:281282.
  • 4
    Birns J, Malone-Lee JG, and the oxybutynin CR Study Group. Controlled-release oxybutynin maintains efficacy with a 43% reduction in side effects compared to conventional treatment. Neurourol Urodyn 1997;16:429430.
  • 5
    Dmchowski R, Staskin D, Appell R, et al. The efficacy, effectiveness, and safety of transdermal oxybutynin in patients with overactive bladder. Neurourol Urodyn 2003;22:533534.
  • 6
    Abrams P, Freeman RM, Anderstrom C, Mattiasson A. Efficacy and tolerability of tolterodine vs oxybutynin and placebo in patients with detrusor instability. Br J Urol 1998;81:801810.DOI: 10.1046/j.1464-410X.1998.00717.x
  • 7
    Van Kerrebroeck PEVA, Serment G, Dreher E. Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder. Neurourol Urodyn 1997;16:478479.
  • 8
    Rudy D, Cline K, Goldberg K, Harris R. A multicenter randomized, placebo controlled trial of trospium chloride in overactive bladder patients. Neuurol Urodyn 2004;23:600601.
  • 9
    Juenemann K, Hessdoerfer E, Unamba-Oparah I, et al. Propiverine Hydrochloride immediate (IR) and extended release (ER): comparison of efficacy and tolerability in patients with overactive bladder. Neurourol Urodyn 2004;23:599600.
  • 10
    Chapple C, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Ridder A. Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder. Neurourol Urodyn 2003;22:534535.
  • 11
    Hill S, Khullar V. Darifenacin, a muscarinic receptor antagonist with selectivity for M3 receptors, reduces incontinence and nocturia in patients with overactive bladder. Neurourol Urodyn 2004;23:602603.
  • 12
    Herbison P, Hay-Smith J, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003;326:841844.
  • 13
    Wilson D. Nonsurgical management of incontinence. In: MacleanAB, CardozoLD, editors. Incontinence in Women. RCOG Press, 2002 Chapter 16.
  • 14
    Robinson D, Cardozo L, Akeson M, Hvistendhal G, Riis A, Norgaard JP. Anti-diuresis—for the control of daytime incontinence. Int Urogynecol J 2002;13:S6.
  • 15
    Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy for voiding disorders: current state of the art. Eur Urol 2003;44:165174.DOI: 10.1016/S0302-2838(03)00250-1